Asian Bio Company CEO Interview - Largest network of private cord blood banks in Asia Pacific (24/11/2009)
Cordlife Pte Ltd （Singapore）
 CordLife is Singapore's first private cord blood bank, operating since 2001. CordLife operates the largest network of private cord blood banks in Asia Pacific, with full stem cell and tissue processing and cryopreservation storage facilities in Singapore, Hong Kong, Indonesia and India as well as marketing presence throughout the region. We interviewed the company’s Group Chief Executive Officer, Mr. Steven Fang, about the company’s business and perspective. 
|
 |
Asian bio company interview – Custom manufacturing for cell therapy (17/08/2009)
Lonza （Singapore）
Headquartered in Basel, Switzerland, Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Lonza is currently building mammalian cell culture manufacturing facilities in Singapore. The company has just announced its plan to build another facility in Singapore for their cell therapy business. We interviewed Dr. Patrick Lambert, Business Director – Asia, about the company’s business plan and prospect.
|
|
Asian Bioventure CEO Interview - Preclinical CRO with breeding facility and translational imaging capability (06/05/2009)
Maccine Pte Ltd （Singapore）
 Maccine Pte Ltd is a preclinical contract research organization (CRO) which provides innovative discovery support and quality safety assessment services to the global pharmaceutical and biotech industry. We interviewed the company’s new Chief Executive Officer, Mr. Leigh Berryman, about the company’s business and perspective.
|
|
Chemical EPIgenomics Symposium @ Singapore (12/03/2009)
【Announcement】 （）
This symposium organized by Japan's renowned Waseda University, Institute of Chemical Biology, and Singapore's National University of Singapore, Medicinal Chemistry Programme, Life Sciences Institute, will provide insight into the new research field of Chemical EPI Genomics - a synergistic combination of three hot research areas of Stem Cell Biology, Epigenetics and Chemical Biology.
|
|
New Hopes for Burn Victims – The Answers Found Within Yourself (01/06/2008)
Japan Tissue Engineering Co., Ltd. （Japan）
 Although there are some 16,000 new burn patients every year in Japan, only 5000 severely burned victims are eligible to receive treatment through tissue engineering technology. Now, with new autograft technology, more can be done for burn victims.
|
|
Japan's BioVentures Interview - Oncolys BioPharma Inc. (09/05/2008)
Oncolys BioPharma Inc. （Japan）
 Oncolys BioPharma Inc. (“Oncolys”) was incorporated in March 2004 to develop and commercialize the product of the research led by Dr. Toshiyoshi Fujiwara, Associate Professor, Okayama University.
|
|
Japan's Bioventures Today - M's Science Corporation (30/01/2008)
M's Science Corporation （Japan）
 M's Science Corporation (“M's Science”) is a venture company established in November 2000 with the mission to “create new drugs by state-of-the-art research to improve human health.” M's Science was founded by Dr Shiro Mita, former director and general manager of research and development at Santen Pharmaceutical Co., Ltd. The company develops promising drug candidates discovered internally or licensed from other companies.
|
|
Japan's Bioventures Today - Japan Animal Referral Medical Center (15/12/2007)
Japan Animal Referral Medical Center （Japan）
 Japan Animal Referral Medical Center (JARMeC) is one of the most comprehensive medical centers for animals in Japan. Established in Kanagawa prefecture in June 2007, JARMeC was founded by a group of the Japan’s top veterinarians. Dr. Yoshihisa Yamane, the chairman of the Japan Veterinary Medical Association, is the key expert who addresses various issues in the animal healthcare system in Japan.
|
|
Japan's BioVentures Today - Medical Collective Intelligence Co., Ltd. (30/10/2007)
Medical Collective Intelligence Co., Ltd. （Japan）
 Medical Collective Intelligence Co., Ltd. (“MCI”) is a venture company that specializes in providing marketing support services for pharmaceutical and healthcare companies. MCI was established in May 2007 as a spin off company from a management consulting company, Link Consulting Associates Japan Corporation (“LCA-J”).
|
|
Japan's Bioventures Today - CanBas Co., Ltd. (30/09/2007)
CanBas Co., Ltd. （Japan）
 CanBas Co., Ltd. (“CanBas”) is a venture company that develops innovative cancer drugs and diagnostic products with a focus on G2 checkpoint of a cell cycle.
|
|
Specialty pharma that addresses unmet medical needs (30/08/2007)
UMN Pharma Inc. （Japan）
 UMN Pharma Inc (“UMN Pharma”) is a venture company dedicated to developing innovative pharmaceutical products that address unmet medical needs - and hence, the name of the company.
|
|
Japan's Bioventures Today - Link Genomics, Inc. (15/07/2007)
Link Genomics, Inc. （Japan）
 Link Genomics, Inc. (“Link Genomics”) is a venture company that focuses on the development of diagnostic and therapeutic products for various cancers based on its proprietary gene analysis technology.
|
|
Japan's Bioventures Today - NanoCarrier Co., Ltd. (15/06/2007)
NanoCarrier Co., Ltd. （Japan）
 NanoCarrier Co., Ltd. (“NanoCarrier”) is a Japanese bioventure company that focuses on the research and development of drugs with a unique nanosized drug delivery system (DDS) technology.
|
|
Bio Companies in Asia - Developing vaccine using novel adjuvant (13/03/2007)
NewBiomed PIKA Pte Ltd （Singapore）
NewBiomed PIKA Pte Ltd (“NewBiomed PIKA”) is a bioventure company established in 2003 in Singapore. The company develops various vaccines including those for influenza, hepatitis B and cancer using its proprietary adjuvant technology.
|
|
Japan's Bioventures Today - ImmunoFrontier, Inc. (15/01/2007)
ImmunoFrontier, Inc. （Japan）
 ImmunoFrontier, Inc. (“ImmunoFrontier”) is a Japanese drug discovery venture company which focuses on the development of cutting-edge therapeutic vaccines for cancers and immunotherapeutics. ImmunoFrontier was established in October 2004 as a spin-off company to commercialize the result of a research conducted by Professor Hiroshi Shiku from the School of Medicine, Mie University in Japan.
|
|
Japan's Bioventures Today - Chiome Bioscience Inc. (15/12/2006)
Chiome Bioscience Inc. （Japan）
 Chiome Bioscience, Inc. (“Chiome”) is a Japanese venture company that specializes in developing monoclonal antibody products. It was established in February 2005 as a spin-off company from RIKEN, an independent administrative institution under the Ministry of Education, Culture, Sports, Science and Technology in Japan.
|
|
Japan's Bioventures Today - Bio Matrix Research, Inc. (30/10/2006)
Bio Matrix Research, Inc. （Japan）
 Bio Matrix Research, Inc. (BMR) was established in March 2002 as a spin-off company from the Tokyo University of Science. BMR’s business is based on the result of research on genome analysis information from the Murakami Laboratory of the University’s Faculty of Industrial Science and Technology. Professor Yasufumi Murakami, vice president of BMR, has 20-years experience in genome research.
|
|
Japan's Bioventures Today - Immuno-Biological Laboratories Co., Ltd. (30/07/2006)
Immuno-Biological Laboratories Co., Ltd. （Japan）
 Immuno-Biological Laboratories Co., Ltd. (“IBL”) is is a well-established bioventure company with a history of more than 20 years. Founded in September 1982, IBL has been focusing on the research and development of antibodies against proteins related to cancers, inflammation, and brain and nervous system disorders.
|
|
Japan's BioVentures Today - Hubit Genomix, Inc. (15/05/2006)
HuBit Genomix, Inc. （Japan）
 HuBit Genomix, Inc. (“HuBit”) was established by the group of Japanese scientists in advanced medical research field in April 2000, the year that unraveling of all human genome sequences was announced. The company was initially set up under the name of Medical Genome Systems Co., Ltd. to create optimum medical care service using latest medical technologies and data obtained through close relationship with local community. The company changed its name to HuBit Genomix, Inc. in March 2001.
|
|
Japan's Bioventures Today - Noas Medical Co., Ltd. (15/04/2006)
Noas Medical Co., Ltd. （Japan）
 Noas Medical Co Ltd (Noas) is a Japanese venture company that imports, manufactures and sells orthopedic instruments including artificial joints, related instruments and accessories.
|
|
